BR112013016809A2 - composições de hidratação celular - Google Patents

composições de hidratação celular

Info

Publication number
BR112013016809A2
BR112013016809A2 BR112013016809A BR112013016809A BR112013016809A2 BR 112013016809 A2 BR112013016809 A2 BR 112013016809A2 BR 112013016809 A BR112013016809 A BR 112013016809A BR 112013016809 A BR112013016809 A BR 112013016809A BR 112013016809 A2 BR112013016809 A2 BR 112013016809A2
Authority
BR
Brazil
Prior art keywords
active component
subcomponent
clathrate
hydration
cellular system
Prior art date
Application number
BR112013016809A
Other languages
English (en)
Inventor
Szente Lajos Hu Hu
Original Assignee
Eastpond Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastpond Lab Ltd filed Critical Eastpond Lab Ltd
Publication of BR112013016809A2 publication Critical patent/BR112013016809A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Fodder In General (AREA)

Abstract

composições de hidratação celular a invenção refere-se a uma composição que interage com um sistema celular biológico que inclui moléculas bioativas com superfícies biomoleculares, componentes celulares e moléculas de água com uma densidade específica. a composição inclui um componente biologicamente ativo que é construído para aumentar a atividade de um sistema celular biológico pelo aumento da hidratação de um ou mais componentes deste sistema celular. o componente ativo pode incluir um subcomponente clatrato de carboidrato primário que aumenta a estrutura de ligação de h da água, e um subcomponente de soluto secundário. o componente biologicamente ativo pode incluir um complexo de inclusão que é feito de um componente clatrato e um composto formador de complexo. o subcomponente clatrato pode incluir amiloses ou ciclodextrinas. a invenção refere-se também a uma bebida e a um método que aumentam a hidratação celular em uma animal, tal como um humano
BR112013016809A 2010-12-31 2010-12-31 composições de hidratação celular BR112013016809A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/003503 WO2012090018A1 (en) 2010-12-31 2010-12-31 Cellular hydration compositions containing cyclodextrins

Publications (1)

Publication Number Publication Date
BR112013016809A2 true BR112013016809A2 (pt) 2016-09-27

Family

ID=44146587

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013016809A BR112013016809A2 (pt) 2010-12-31 2010-12-31 composições de hidratação celular

Country Status (8)

Country Link
EP (2) EP4043037A1 (pt)
JP (1) JP2014502612A (pt)
CN (1) CN103491981B (pt)
AU (2) AU2010366535A1 (pt)
BR (1) BR112013016809A2 (pt)
CA (1) CA2822995C (pt)
RU (1) RU2013133723A (pt)
WO (1) WO2012090018A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
WO2014060548A1 (de) * 2012-10-17 2014-04-24 Sapiotec Gmbh Anthocyanidin-komplex zur behandlung von multiplem myelom
DK2919791T3 (da) 2012-11-15 2017-07-17 Sapiotec Gmbh Delphinidin-kompleks som antiflogistisk eller immunsuppressivt aktivt stof
CA2893883A1 (en) 2012-12-11 2014-06-19 Sapiotec Gmbh Delphinidin for combating melanoma cells
EP2968083B1 (en) 2013-03-12 2021-09-22 Primal Therapies, Inc. Dental composition comprising chelator and base
EP2913366A1 (de) * 2014-02-28 2015-09-02 SapioTec GmbH Anthocyanidin-Komplex
JP6075345B2 (ja) * 2014-09-24 2017-02-08 株式会社東洋新薬 コンドロイチン製剤
SG11202108608SA (en) 2019-02-14 2021-09-29 Cyclopure Inc Charge-bearing cyclodextrin polymeric materials and methods of making and using same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU184066B (en) * 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
JPS6094912A (ja) 1983-10-28 1985-05-28 Masashige Suzuki 体内中性脂肪低減剤
EP0406811A3 (en) * 1989-07-03 1991-08-28 Ajinomoto Co., Inc. Novel clathrate compounds and a drug comprising them
CA2013485C (en) * 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
US5221735A (en) * 1991-02-25 1993-06-22 Hoffmann-La Roche Inc. Cyclodextrin-polyene inclusion complexes
US5681380A (en) * 1995-06-05 1997-10-28 Kimberly-Clark Worldwide, Inc. Ink for ink jet printers
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
ATE289703T1 (de) * 1999-05-20 2005-03-15 Bayer Ag Verfahren zur herstellung von pi-konjugierten polymeren
AU4866001A (en) 2000-03-28 2001-10-08 Farmarc Nederland Bv Alprazolam inclusion complexes and pharmaceutical compositions thereof
JP4675457B2 (ja) * 2000-06-20 2011-04-20 高砂香料工業株式会社 ワニリルアルコール誘導体のサイクロデキストリン包接化合物、及びそれを含有する組成物
US6884885B2 (en) * 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
CA2463687A1 (en) 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
PT1499361E (pt) 2002-04-19 2012-11-22 Novartis Ag Novos biomateriais, sua preparação e utilização
MXPA04012880A (es) 2002-08-19 2005-07-05 Art Jen Complexus Inc Composiciones que comprenden complejante de grasa alimentaria y metodos para su uso.
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
EP1447013A1 (en) 2003-02-14 2004-08-18 Wacker-Chemie GmbH Method for reducing the glycemic index of food
US7105195B2 (en) 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
WO2006004574A2 (en) 2004-02-19 2006-01-12 Abbott Laboratories Method for using gamma cyclodextrin to control blood glucose and insulin secretion
MX2007003718A (es) * 2004-09-27 2007-04-23 Cargill Inc Complejos de inclusion de ciclodextrina y metodos para preparar los mismos.
FR2876914A1 (fr) * 2004-10-21 2006-04-28 Pierre Fabre Medicament Sa Complexe comprenant un antibiotique, une cyclodextrine et un agent d'interaction
MX2007015862A (es) * 2005-06-13 2008-02-22 Cargill Inc Complejos de inclusion de ciclodextrina y metodos para preparar los mismos.
US8512789B2 (en) 2005-11-23 2013-08-20 The Coca-Cola Company High-potency sweetener composition with dietary fiber and compositions sweetened therewith
EP2027136A4 (en) * 2006-06-13 2011-08-03 Cargill Inc Large part cyclicxtrin inclusion complexes and method for their preparation
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
US20110177161A1 (en) * 2007-05-24 2011-07-21 Dr. Reddy's Laboratories Limited Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin
US20090023682A1 (en) 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
MX2010004803A (es) 2007-10-31 2010-09-09 Diffusion Pharmaceuticals Llc Una nueva clase de composiciones terapeuticas que mejoran la difusion de moleculas pequeñas.

Also Published As

Publication number Publication date
EP4043037A1 (en) 2022-08-17
CN103491981B (zh) 2017-11-10
RU2013133723A (ru) 2015-02-10
AU2016201846A1 (en) 2016-04-21
AU2010366535A1 (en) 2013-07-11
CA2822995C (en) 2021-05-11
JP2014502612A (ja) 2014-02-03
WO2012090018A1 (en) 2012-07-05
EP2658578A1 (en) 2013-11-06
CA2822995A1 (en) 2012-07-05
CN103491981A (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
BR112013016809A2 (pt) composições de hidratação celular
GT200600112A (es) Composiciiones de tigeciclina y metodos de preparacion
CO6720961A2 (es) Imidazopiridazinas sustituidas
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CL2008001674A1 (es) Dominio variable simple (dab) de inmunoglobulina anti-fator de crecimiento endotlial vascular (vegf); acido nucleoico que lo codifica; vector y celula huesped; metodo de produccion; antagonosta de vegf que comprende el dab; composiicon que comprende al antagonista; y uso del antagonista para prepara un medicamento.
BR112015006426A2 (pt) composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, proteína e baixos níveis de eletrólitos
EA201391030A1 (ru) Композиции моноциклина для местного применения и способы их применения
EA201791850A1 (ru) Борсодержащие малые молекулы
BR112014008255A2 (pt) composições antimicrobianas e métodos empregando as mesmas
BR112015013700A8 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
BR112012018104A2 (pt) tratamento de doenças cardíacas
CO6680663A2 (es) Composiciones pesticidas producidas de piranosas, composiciones que las contienen y su proceso de obtención
BR112015027536A2 (pt) composição compreendendo mistura de bactérias ácidas lácticas, bem como uso da referida mistura
BR112013031414A2 (pt) métodos para converter material lignocelulósico em produtos úteis
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
CL2012003516A1 (es) Compuesto derivado de 5-fenil-5-trifluorometil-4,5-dihidroisoxazol; composicion que lo comprende; y su uso para controlar piojos de mar en peces.
ECSP11011297A (es) Proteinas ligadoras il-17
BR112012015501A8 (pt) Processo de biodegradação e composição
BRPI1102843B8 (pt) Composições de limpeza límpidas, de baixa irritação com ph relativamente baixo
BR112013031307A2 (pt) métodos para tratamento de material lignocelulósico
PE20121709A1 (es) Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
BR112017025459A2 (pt) composição, método para tratamento de doença falciforme, kit, método para detecção de polissulfato pentosano de sódio (pps)

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C08B 37/16 (2006.01), A61K 31/198 (2006.01), A61K